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Cav3.2 T-type Ca2þ channels targeted by H2S, a gasotransmitter, participate in cyclophosphamide-
induced cystitis and bladder pain. Given that zinc selectively inhibits Cav3.2 among T-channel iso-
forms and also exhibits antioxidant activity, we examined whether polaprezinc (zinc-L-carnosine), a
medicine for peptic ulcer treatment and zinc supplementation, reveals preventive or therapeutic effects
on bladder inﬂammation and/or pain in the mouse with cyclophosphamide-induced cystitis, a model for
interstitial cystitis. Systemic administration of cyclophosphamide caused cystitis-related symptoms
including increased bladder weight and vascular permeability, and histological signs of bladder edema,
accompanied by bladder pain-like nociceptive behavior/referred hyperalgesia. All these symptoms were
signiﬁcantly attenuated by oral preadministration of polaprezinc at 400 mg/kg. The same dose of
polaprezinc also prevented the increased malondialdehyde level, an indicator of lipid peroxidation, and
protein upregulation of cystathionine-g-lyase, an H2S-generating enzyme, but not occludin, a tight
junction-related membrane protein, in the bladder tissue of cyclophosphamide-treated mice. Oral
posttreatment with polaprezinc at 30e100 mg/kg reversed the nociceptive behavior/referred hyper-
algesia in a dose-dependent manner without affecting the increased bladder weight. Together, our data
show that zinc supplementation with polaprezinc prevents the cyclophosphamide-induced cystitis
probably through the antioxidant activity, and, like T-channel blockers, reverses the established cystitis-
related bladder pain in mice, suggesting novel therapeutic usefulness of polaprezinc.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hydrogen sulﬁde (H2S), a gasotransmitter, is produced from L-
cysteine by multiple enzymes including cystathionine-g-lyase
(CSE). We have reported that H2S in the peripheral tissue and/or
spinal cord causes pain or hyperalgesia by enhancing the activity of
Cav3.2 T-type Ca2 þ channels (1e3). The H2S/Cav3.2 pathway also
plays a role in the maintenance of neuropathic pain (4, 5) and in
processing of visceral nociception including colonic, pancreatic and: þ81 6 6730 1394.
wabata).
acological Society.
Production and hosting by Elseviebladder pain (6e8). In the mice with cyclophosphamide-induced
cystitis, recognized as an animal model for interstitial cystitis, CSE
protein is upregulated in the bladder tissue, and H2S formed by CSE
appears to enhance Cav3.2 function, leading to bladder pain and
also acceleration of cystitis itself (8). Like L-cysteine (9), H2S en-
hances Cav3.2 function possibly by interacting with Zn2þ bound to
the histidine residue at position 191 in the Cav3.2 molecule, and
zinc chloride, in turn, inhibits Cav3.2 currents in vitro and H2S-
induced colonic pain and referred hyperalgesia in vivo (3, 10).
Polaprezinc, a zinc-L-carnosine chelate compound, is clinically
used for treatment of gastric ulcer. Accumulating evidence suggests
that polaprezinc exerts gastric mucosal cytoprotection and pro-
motes ulcer healing through multiple mechanisms including anti-
oxidant activity (11e15). In addition, polaprezinc increases bloodr B.V. All rights reserved.
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zinc deﬁciency (16, 17). Considering plenty of evidence that
zinc itself shows antioxidant activity (18e21), we hypothesized
that zinc supplementation with polaprezinc might attenuate
cyclophosphamide-induced cystitis and/or bladder pain probably
by decreasing free radicals or inhibiting Cav3.2 channel activity.
Here we show that polaprezinc prevents cyclophosphamide-
induced cystitis, and reverses the established cystitis-related
bladder pain.
2. Materials and methods
2.1. Experimental animals
Female ddY mice weighing 18e25 g were purchased from Kiwa
Laboratory Animals Co., Ltd. (Wakayama, Japan). The animals were
housed in a temperature-controlled room under a 12-h day/night
cycle at about 24 C and had free access to food and water. All
experimental protocols were approved by the Committee for the
Care and Use of Laboratory Animals at Kinki University.
2.2. Creation of cyclophosphamide-induced cystitis in mice
As described previously (22, 23), cystitis was induced in mice by
i.p. administration of cyclophosphamide at 300 mg/kg. Bladder
pain-like nociceptive behavior was observed from 3.5 to 4 h after
the administration of cyclophosphamide, followed by assessment
of referred hyperalgesia, as described below. The mice were then
killed by cervical dislocation, and the bladder was removed for
measurement of the wet-tissue weight.
2.3. Assessment of bladder pain-like nociceptive behavior and
referred hyperalgesia in mice
According to the previously described method (22, 24) with
minor modiﬁcations (23), the mouse was placed on a raised wire
mesh under a transparent plastic box (23.5  16.6  12.4 cm), and
acclimated to experimental environment for 1 h. Bladder pain-like
nociceptive behavior, licking of the external urethral opening, was
observed and counted from 3.5 to 4 h after cyclophosphamide
administration. Immediately after the observation of nociceptive
behavior, the region between the anus and urethral opening was
stimulatedmechanically using four distinct von Frey ﬁlaments with
strengths of 0.008, 0.07, 0.4 and 1.0 g, in an ascending order of
strength, for the determination of referred hyperalgesia. The me-
chanical stimulation with each ﬁlament was applied 10 times at
intervals 5e10 s. To prevent ‘wind-up’ effects or desensitization,
repeated stimulation of the same point was avoided. The nocicep-
tive behavior was scored as follows: 0 ¼ no response; 1¼ licking or
biting of the external urethral opening and/or the surrounding
area, leaving the position, bending of the trunk, raising the upper
half of the body and thrashing limbs; 2 ¼ jumping. Data are
expressed as the total score for responses to 10 challenges with
each ﬁlament.
2.4. Measurement of vascular permeability in the bladder tissue
The mice received i.p. administration of cyclophosphamide at
300 mg/kg immediately after intravenous injection of Evans blue at
30 mg/kg. The bladder tissue was excised 4e4.5 h after cyclo-
phosphamide treatment, dried at 60 C for 24 h, and incubated in
300 mL of formamide solution maintained at 37 C for 24 h.
Absorbance at 620 nm in the supernatant was measured with a
spectrometer.2.5. Histological evaluation of the bladder edema
The isolated bladder was ﬁxed, embedded in parafﬁn,
sectioned and stained with haematoxylin and eosin for histolog-
ical analysis. The extent of bladder edema was determined by
scoring as follows: 0 ¼ no edema; 1 ¼ edema limited to the sub-
mucosa, the width of which does not exceed the width of the
detrusor; 2 ¼ edema present in the bladder wall but not the
detrusor and the width of the submucosal region greater than, but
less than twice than, the width of detrusor; 3 ¼ edema present in
the bladder wall, possibly including occasional areas of the
detrusor, and the width of the submucosal region greater than
twice the width of detrusor (25).2.6. Measurement of malondialdehyde levels in the bladder tissue
Malondialdehyde levels in the bladder tissue were determined
using NWLSS™Malondialdehyde Assay Kit (Northwest Life Science
Specialties, WA, USA). Brieﬂy, the excised bladder was homoge-
nized in 10 volumes of a cold phosphate buffer with EDTA and
centrifuged. The supernatant was incubated at 60 C for 60 min
after addition of butylated hydroxytoluene, 1 M phosphoric acid
and 2-thioberbituric acid. After centrifugation of the mixture,
absorbance at 532 nm in the supernatant was measured with a
spectrometer.2.7. Western blot analysis
The isolated bladder was frozen in liquid nitrogen, and there-
after homogenized in a RIPA buffer (PBS, 0.5% sodium deoxycholate,
1% Igepal Ca-630 and 0.1% SDS), containing 0.1mg/mL PMSF, 0.15 U/
mL aprotinin and 1 mM sodium orthovanadate. After centrifuga-
tion, bromophenol blue and 2-mercaptoethanol were added to the
supernatant. Proteins in the sample were denatured at 95e100 C
for 5 min and separated by electrophoresis on 7.5% (for the detec-
tion of ZO-1) or 12.5% [for the detection of CSE, occludin and gly-
celaldehyde-3-phophate dehydrogenase (GAPDH)] SDS-
polyacrylamide gel (Wako Pure Chem., Osaka, Japan) for 2 h, and
transferred to a polyvinylidene diﬂuoride membrane for 1 h. The
membrane was blocked with blocking solution containing 5% skim
milk, 137 mM NaCl, 0.1% Tween 20 and 20 mM TriseHCl (pH 7.6).
After washing the membrane was incubated with an anti-CSE
rabbit polyclonal antibody (1:1000) (SigmaeAldrich Japan, Ishi-
kari, Japan), an anti-occludin rabbit polyclonal antibody (1:250)
(Invitrogen Corporation, Camarillo, CA, USA), an anti ZO-1 rabbit
polyclonal antibody (1:1000) (Invitrogen Corporation), an anti
GAPDH rabbit polyclonal antibody (1:5000) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) at 4 C overnight. After washing, the
membrane was incubated with the HRP-conjugated anti rabbit IgG
antibody (1:5000) (Santa Cruz Biotechnology) for 1 h. Immuno-
positive bands (CSE, 43e47 kDa; occludin, 65e79 kDa; ZO-1,
225 kDa; GAPDH, 37 kDa) were visualized by the enhanced
chemiluminescence detection reagent (Nacalai Tesque, Inc., Kyoto,
Japan). The resulting ﬁlms were scanned and quantiﬁed using
densitometric software (Image J downloaded from http://imagej.
nih.gov/ij/download.html).2.8. Rota-rod test
The rota-rod performance was determined using Rotor Load®
(Natsume Seisakusho Co. Ltd., Tokyo, Japan). The latency to fall was
determined three times with the cut-off time of 300 s, and the
results were averaged.
Fig. 2. Effect of pretreatment with polaprezinc on cyclophosphamide-induced in-
ﬂammatory symptoms in mouse bladder. Polaprezinc (Pola) at 400 mg/kg or vehicle
(V) was administered p.o. to mice 1 h before i.p. administration of cyclophosphamide
(CP) at 300 mg/kg. (a) Typical photographs of bladder tissue from mice treated with CP
after p.o. Pola or V. Scale bars indicate 1 mm. (b) Histological scores of bladder edema
in mice treated with CP after p.o. Pola or V. (c) Vascular permeability in the bladder
tissue. Evans blue at 50 mg/kg was administered i.v. immediately before i.p. CP or
vehicle. The results are presented as % of the control (the average in the V þ V group).
Data show the mean with S.E.M. for 6e9 mice. **P <0.01 vs V þ V. yyP <0.01 vs V þ CP.
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Poraprezinc was a gift from Zeria Pharmaceutical Co., Ltd.
(Tokyo, Japan). Cyclophosphamide monohydrate and bacrofen
were purchased from SigmaeAldrich (St. Louis, MO, USA). Por-
aprezinc was suspended in 0.5% methylcellulose, while cyclo-
phosphamide and bacrofenwere dissolved in saline. Polaprezinc at
30, 100, 200 or 400 mg/kg was administered orally 1 h before or 3 h
after i.p. administration of cyclophosphamide at 300 mg/kg. Bac-
lofen was administered i.p. 30 min before the rota-rod test.
2.10. Statistical analysis
Data are represented as means with S.E.M. Statistical signiﬁ-
cance for parametric data was analyzed by Student's t-test for
comparison between 2 groups and by analysis of variance followed
by Tukey's test for multiple comparisons. For non-parametric an-
alyses, the KruskaleWallis H-test followed by a least signiﬁcant
difference-type test was employed for multiple comparisons. Sig-
niﬁcance was set at a level of P <0.05.
3. Results
3.1. Oral preadministration of polaprezinc prevents inﬂammatory
symptoms and bladder pain in mice with cyclophosphamide-
induced cystitis
Systemic administration of cyclophosphamide at 300 mg/kg
caused increases in bladder weight (Fig. 1a), histological edema
scores and vascular permeability (Fig. 2), accompanied by bladder
pain-like nociceptive behavior and referred hyperalgesia (Fig. 1b, c),Fig. 1. Effect of pretreatment with polaprezinc on cyclophosphamide-induced bladder
pain-like nociceptive behavior and referred hyperalgesia accompanying cystitis in
mice. Polaprezinc (Pola) at 200 (a) or 400 mg/kg (a, b, c) or vehicle (V) was adminis-
tered p.o. to mice 1 h before i.p. administration of cyclophosphamide (CP) at 300 mg/
kg. Bladder pain-like nociceptive behavior was observed 3.5e4 h after i.p. CP (b),
followed by the evaluation of referred hyperalgesia (c), and then the mice were killed
for measurement of the bladder weight (a). Data show the mean with S.E.M. for 8e10
(a) or 11e24 (b, c) mice. *P <0.05, **P <0.01 vs. V þ V. yyP <0.01, yyyP <0.001 vs. V þ CP.being consistent with our previous work (8). The
cyclophosphamide-induced cystitis symptoms and bladder pain/
referred hyperalgesia were prevented by oral preadministration of
polaprezinc at 400 mg/kg in mice (Figs. 1 and 2).
3.2. Oral preadministration of polaprezinc inhibits lipid
peroxidation in the bladder tissue of mice with cyclophosphamide-
induced cystitis
To test whether polaprezinc affects the redox state in the
bladder after cyclophosphamide challenge, we determined the
levels of malondialdehyde, an indicator of lipid peroxidation, in
the mouse bladder. Bladder malondialdehyde levels almost
doubled 4 h after i.p. administration of cyclophosphamide (Fig. 3),
in agreement with independent evidence in mice (26). SystemicFig. 3. Effect of pretreatment with polaprezinc on malondialdehyde levels in the
bladder tissue of mice with cyclophosphamide-induced cystitis. Polaprezinc (Pola) at
400 mg/kg or vehicle (V) was administered p.o. to mice 1 h before administration of i.p.
cyclophosphamide (CP) at 300 mg/kg. The mice were killed 4e4.5 h after i.p. CP, and
the bladder was removed for measurement of malondialdehyde levels in the bladder
tissue. Data show the mean with S.E.M. for 7e9 mice. **P <0.01 vs V þ V. yP <0.05 vs
V þ CP.
Fig. 5. Effect of posttreatment with polaprezinc on the cyclophosphamide-induced
bladder pain-like nociceptive behavior and referred hyperalgesia accompanying
cystitis in mice. Polaprezinc (Pola) at 30 or 100 mg/kg, or vehicle (V) was administrated
p.o. to mice 3 h after i.p. administration of cyclophosphamide (CP) at 300 mg/kg.
Bladder pain-like nociceptive behavior was observed 3.5e4 h after i.p. CP (b), followed
by the evaluation of referred hyperalgesia (c), and then the mice were killed for
measurement of the bladder weight (a). Data show the mean with S.E.M. for 10e14
mice. **P <0.01, ***P <0.001 vs. V þ V. yP <0.05, yyP <0.01 vs. V þ CP.
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vented the cyclophosphamide-induced increase in the bladder
malondialdehyde levels (Fig. 3).
3.3. Effects of oral preadministration of polaprezinc on expression
levels of an H2S-generating enzyme and tight junction-related
proteins in the bladder of mice with cyclophosphamide-induced
cystitis
In the bladder tissue of mice with cyclophosphamide-induced
cystitis, great upregulation of CSE, an H2S-generating enzyme,
occurred at protein levels (Fig. 4), as reported previously (8). This
upregulation of CSE was signiﬁcantly suppressed by preadminis-
tration of polaprezinc at 400 mg/kg (Fig. 4). To assess the blood-
urine barrier function in the urothelium, we determined protein
levels of two major superﬁcial urothelial cell tight junction-related
proteins, occludin, a membrane protein, and ZO-1 that anchors the
membrane proteins to the cytoskeleton (27). The mice treated with
cyclophosphamide showed a signiﬁcant decrease in protein levels
of occludin, but not ZO-1, in the bladder tissue, which was not
signiﬁcantly attenuated by preadministration of polaprezinc at
400 mg/kg (Fig. 4).
3.4. Oral administration of polaprezinc reverses the established
cystitis-related bladder pain/referred hyperalgesia in the mice with
cyclophosphamide-induced cystitis
Given our previous evidence that T-type Ca2þ channel blockers
not only partially prevented the cyclophosphamide-induced
bladder inﬂammation and pain, but also reversed the established
bladder pain (8), we asked whether supplementation of zinc,
known to inhibit Cav3.2 T-type Ca2þ channels, with polaprezinc
reverses the established bladder pain/referred hyperalgesia.
Polaprezinc, when administered orally at 30e100 mg/kg, relatively
low doses, 3 h after cyclophosphamide challenge, suppressed the
bladder pain-like nociceptive behavior and referred hyperalgesia in
a dose-dependent manner (Fig. 5b, c), without affecting the
increased bladder weight (Fig. 5a). It is noteworthy that these
therapeutically effective doses are lower than the effective dose,
400 mg/kg, of preadministered polaprezinc.Fig. 4. Effect of pretreatment with polaprezinc on the protein levels of cystathionine-g-lyase
panels indicate typical photographs of Western blotting for cystathionine-g-lyase (CSE), occ
were quantiﬁed by densitometry. Polaprezinc (Pola) at 400 mg/kg or vehicle (V) was adminis
The mice were killed 4 h after i.p. CP, and then bladder was excised for Western blotting. Da
vs. V þ V. yP <0.05 vs. V þ CP.3.5. Oral administration of polaprezinc does not affect motor
coordination in mice
Polaprezinc, administered orally at 100 and 400 mg/kg, doses
effective for posttreatment and preteatment, respectively, did not
signiﬁcantly impair rota-rod performance, an indicator of motor, occludin or ZO-1 in the bladder of mice with cyclophosphamide-induced cystitis. Top
ludin and ZO-1 in the bladder. Protein levels of CSE, occludin and ZO-1 in the bladder
tered p.o. to mice 1 h before i.p. administration of cyclophosphamide (CP) at 300 mg/kg.
ta show the mean with S.E.M. for 7 (CSE and occludin) or 10e11 (ZO-1) mice. **P <0.01
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relaxant, at 10 mg/kg shortened the latency to fall (Fig. 6).4. Discussion
Polaprezinc, zinc-L-carnosine, is used for treatment of gastro-
intestinal ulcer and zinc deﬁciency. Polaprezinc exerts mucosal
cytoprotection mainly by decreasing reactive oxygen species
(11e14). Zinc itself is considered to be involved in the cytopro-
tective effects of polaprezinc, because polaprezinc, when admin-
istered orally, is readily converted into zinc and L-carnosine in the
process of absorption, and zinc, but not L-carnosine that is rapidly
degraded, is detectable in the blood (28). It is noteworthy that zinc
sulfate, but not L-carnosine, mimics the anti-apoptotic effect of
polaprezinc in rat intestinal epithelial RIE cells (15). There is also
plenty of evidence that zinc supplementation with zinc chloride
reduces oxidative stress in vivo as well as in vitro through functional
upregulation of antioxidant or antiapoptotic proteins or inhibition
of proapoptotic enzymes (18e21). It is to be noted that polaprezinc
is less toxic than zinc chloride in rat thymocytes (29). These reports
are consistent with the present ﬁndings that preadministered
polaprezinc at 400 mg/kg prevented the cyclophosphamide-
induced cystitis-related symptoms, particularly bladder edema
(see Figs. 1a and 2), although it failed to affect the decreased protein
levels of occludin, a tight junction-related protein (see Fig. 4). The
preventive effects of polaprezinc appear to involve the antioxidant
action of zinc, considering the inhibition of the increased bladder
levels of lipid peroxides by polaprezinc (see Fig. 3).
Tight junction in the urothelium plays an important role in the
formation of blood-urine barrier. The damage to tight junction
causes the disruption of barrier function, which induces the urinary
tract diseases (27). In the present study, we found that the protein
level of occludin, a transmembrane component of tight junction,
but not ZO-1, a scaffolding protein of tight junction, decreased in
the bladder of mice treated with cyclophosphamide. These ﬁndings
are consistent with previous evidence that transmembrane pro-
teins including occludin are more sensitive to toxic agents or in-
ﬂammatory stimuli than scaffold proteins such as ZO-1 (30, 31).
Polaprezinc might improve the cyclophosphamide-induced
bladder edema through suppression of the increased vascular
permeability, because it prevented the enhancement of Evans blue
extravasation, but not the decrease in occludin levels, in the
bladder.
We have reported that the enhancement of Cav3.2 T-type Ca2 þ
channel activity by H2S generated by upregulated CSE, an H2S-Fig. 6. Lack of effect of polaprezinc on the rota-rod performance in mice. (a) Rota-rod
test was performed 30 min after p.o. administration of polaprezinc (Pola) at 100 or
400 mg/kg or vehicle (V) and after i.p. administration of baclofen at 10 mg/kg or V. (b)
Cyclophosphamide (CP) at 300 mg/kg was administrated i.p. to mice 1 h after p.o. Pola.
Rota-rod test was performed 4.5 h after p.o. Pola (3.5 h after i.p. CP). Data show the
mean with S.E.M. for 5e8 (a) or 4e9 (b) mice. *P <0.05 vs. V.forming enzyme, plays a major role in the development and
maintenance of bladder pain in mice with cyclophosphamide-
induced cystitis (8). The inhibition of CSE upregulation by pre-
administered polaprezinc might explain why polaprezinc only
partially prevented the inﬂammatory symptoms, but almost
completely blocked the bladder pain (Figs. 1 and 2). Previously, we
have also shown that the enhanced Cav3.2 T-type Ca2þ channel
activity in nociceptors contributes to the development of bladder
inﬂammation itself (8), in agreement with independent evidence
for involvement of neurogenic inﬂammation in cyclophosphamide-
induced cystitis (32). Given evidence that zinc inhibits Cav3.2, but
not Cav3.1 or Cav3.3, among T-type Ca2þ channel isoforms (9), the
preventive or protective effect of preadministered polaprezinc
against cyclophosphamide-induced cystitis might involve, at least
in part, zinc inhibition of Cav3.2 expressed in sensory neurons. As
did T-type Ca2þ channel blockers (8), polaprezinc even at 100 mg/
kg, a relatively low dose, when administered 3 h after cyclophos-
phamide challenge, reversed the established bladder pain, but not
the increased bladder weight (see Fig. 3), supporting our previous
report that Cav3.2 channels play a critical role in themaintenance of
cyclophosphamide-induced bladder pain (8). The present results
are consistent with our previous reports that zinc chloride sup-
presses the Cav3.2-dependent colonic pain following intracolonic
administration of an H2S donor (10) and the cerulein-induced
pancreatitis-related pain in which the H2S/Cav3.2 pathway plays a
pronociceptive role (33). The preventive and therapeutic effects of
polaprezinc on the cystitis-related pain is not secondary to
impairment of motor coordination in consideration of the results of
the rota-rod test (see Fig. 6).
In conclusion, our data show that zinc supplementation with
polaprezinc prevents the bladder edema and reverses the bladder
pain in the mouse with cyclophosphamide-induced cystitis, a
model for interstitial cystitis, most probably through its antioxidant
activity and blockade of Cav3.2 T-type Ca2þ channels. Drug re-
proﬁling studies are to develop a new therapeutic application of
existing drugs used for treatment of different diseases, and now
attract many researchers' attention in drug development because
their safety in humans has already been demonstrated (34). Several
fundamental and clinical researchers including our group have
emphasized the therapeutic usefulness of polaprezinc, a safe anti-
peptic ulcer agent, for treatment of oral mucositis (35e37). Here
we propose possible clinical application of polaprezinc as a medi-
cine for treatment of lower urinary tract syndromes including
interstitial cystitis.
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